ClinicalTrials.gg
CompletedNCT02454179KEYNOTE147Updated Sep 12, 2019Results posted

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of pembrolizumab and Acalabrutinib in Squamous Cell Carcinoma of the Head and Neck, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca — 4 open to participants now, 6 under way, 2 of them phase 3. Squamous Cell Carcinoma of Head and Neck · AstraZeneca.

Enrollment
11th of 21
78 · median 78
Started
2015
with 3 others
Phase 2
4 of 22
1 open now
Registered
6th of 22
by date

Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2015, is one of 4 in phase 2, and was the 6th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

4 of the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, or all of them as a file.
02

Study summary

Study of the combination of acalabrutinib (ACP-196) and pembrolizumab in subjects with advanced head and neck squamous cell carcinoma.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • or cytologically confirmed recurrent, or unresectable HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that that has either progressed during or after platinum-based chemotherapy administered for metastatic disease or has recurred during or within 6 months after the completion of platinum-based or adjuvant therapy
  • Presence of radiographically as defined by 1.1
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior (other than HNSCC), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years
  • Known central nervous system and/or carcinomatous meningitis
  • A life-threatening illness, medical condition (including psychiatric conditions) or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of starting study drug
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Arm 1

    pembrolizumab

    Drug: pembrolizumab

  • Experimental
    Arm 2

    acalabrutinib in combination with pembrolizumab

    Drug: pembrolizumab · Drug: Acalabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Overall Response

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: 52 weeks

07

Results

Posted Sep 12, 2019

Participant flow

Participant flow — Overall Study
MilestoneMono Therapy of Pembrolizumab Arm 1Combo Therapy Acalabrutinib + Pembrolizumab Arm 2
Started3939
Enrolled3939
Received study medication3937
Discontinue study3939
Completed00
Not completed3939

Outcome measures

PrimaryNumber of Participants With Overall Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Overall Response
ParticipantsMono Therapy Arm - PembrolizumabCombo Therapy Arm - Acalabrutinib and Pembrolizumab
Number of Participants With Overall Response75

Adverse events

Collected over Safety Analysis tracked from 0 day to 2 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 - Pembrolizumab26/39 (66.7%)12/39 (30.8%)39/39 (100%)
Arm 2 - Acalabrutinib + Pembrolizumab23/37 (62.2%)25/37 (67.6%)37/37 (100%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventArm 1 - PembrolizumabArm 2 - Acalabrutinib + Pembrolizumab
DyspnoeaRespiratory, thoracic and mediastinal disorders0/394/37
Acute Kidney InjuryRenal and urinary disorders0/393/37
PneumoniaInfections and infestations2/393/37
Tumour HeaorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/390/37
PyrexiaGeneral disorders0/392/37
UrosepsisInfections and infestations0/392/37
Respiratory FailureRespiratory, thoracic and mediastinal disorders0/392/37
SepsisInfections and infestations0/392/37
Cardiac Failure CongestiveCardiac disorders2/390/37
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders2/390/37
Most frequent other events
Showing 10 of 90
Most frequent other events
EventArm 1 - PembrolizumabArm 2 - Acalabrutinib + Pembrolizumab
FatigueGeneral disorders20/3914/37
AnaemiaBlood and lymphatic system disorders2/3912/37
DiarrheaGastrointestinal disorders6/3911/37
Decreased AppetiteMetabolism and nutrition disorders7/3911/37
DyspnoeaRespiratory, thoracic and mediastinal disorders5/3911/37
DehydrationMetabolism and nutrition disorders2/3910/37
Oedema PeripheralGeneral disorders4/399/37
NauseaGastrointestinal disorders4/399/37
Weight DecreasedInvestigations5/399/37
PyrexiaGeneral disorders5/398/37

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Mono Therapy Arm - PembrolizumabCombo Therapy Arm - Acalabrutinib + PembrolizumabTotal
Mean62.1 ± 10.4561.4 ± 11.1261.8 ± 10.71
Sex: Female, Male
Sex: Female, Male(Participants)Mono Therapy Arm - PembrolizumabCombo Therapy Arm - Acalabrutinib + PembrolizumabTotal
Female527
Male343569
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mono Therapy Arm - PembrolizumabCombo Therapy Arm - Acalabrutinib + PembrolizumabTotal
Hispanic or Latino426
Not Hispanic or Latino353570
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mono Therapy Arm - PembrolizumabCombo Therapy Arm - Acalabrutinib + PembrolizumabTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American066
White372966
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Mono Therapy Arm - PembrolizumabCombo Therapy Arm - Acalabrutinib + PembrolizumabTotal
United States393776
08

Study locations

1 site
  • Oregon Health and Science University
    Portland, Oregon, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in May 2018, 36 months.

Results were first posted in Sep 2019, 1 year 4 months after primary completion.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 36 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2015
First posted
May 27, 2015
StartActual
May 2015
Primary completionActual
May 2018
CompletionActual
Jul 2018
Results first posted
Sep 12, 2019
Last update
Sep 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02454179
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
May 27, 2015
Start date
May 2015
Primary completion
May 2018
Completion
Jul 2018
Results posted
Sep 12, 2019
Last update
Sep 12, 2019

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion